A Case of Vitiligo Combined with Systemic Lupus Erythematosus Treated with Tofacitinib
DOI: https://doi.org/10.2147/ccid.s448535
2024-03-20
Clinical Cosmetic and Investigational Dermatology
Abstract:Qingxia Lin, 1 Jinrong Zhu, 2 Xuelei Gao 3 1 Department of Dermatology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People's Republic of China; 2 Department of Central Pharmacy, Zhucheng People's Hospital, Weifang, Shandong, People's Republic of China; 3 Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People's Republic of China Correspondence: Xuelei Gao, Department of Hepatopancreatobiliary Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong, People's Republic of China, Email Vitiligo is a skin depigmentation disease resulting from melanocyte destruction and often co-occurring with autoimmune disorders like hyperthyroidism, alopecia areata, pernicious anemia, and systemic lupus erythematosus (SLE). Although various traditional treatments exist for vitiligo, their effectiveness varies considerably. This report presents a unique case of a vitiligo patient with concomitant systemic lupus erythematosus. Remarkably, after a 30-day course of treatment with tofacitinib, complete repigmentation of the white macular rash was achieved, and there were no adverse drug reactions. These findings provide compelling evidence for the efficacy and safety of oral JAK inhibitors, such as tofacitinib, in vitiligo treatment. Additionally, JAK inhibitors can yet be regarded as a promising new treatment option for vitiligo patients with concurrent autoimmune diseases. Keywords: vitiligo, systemic lupus erythematosus, tofacitinib, JAK inhibitors Vitiligo is a common skin depigmentation disorder that significantly impacts patients' appearance and quality of life. With a prevalence rate of 0.5–2%, 1 vitiligo is easy to diagnose and difficult to treat. Current understanding suggests that vitiligo is an autoimmune disease characterized by the dysregulation of the adaptive immune response. 2 Increasing studies have shown that CD8+ T cells and the cytokines they secrete, notably interferon-γ (IFN-γ), by activating the JAK-STAT pathway, appear to play a pivotal role in the autoimmunity of vitiligo. 3 Tofacitinib, an oral Janus kinase (JAK) inhibitor, demonstrates the ability to inhibit lymphocyte-mediated damage to melanocytes by blocking the JAK-STAT signaling pathway. 3 Based on this mechanism of action, we hypothesize that JAK inhibitors hold promise as targeted therapeutic agents for vitiligo. We report a case of vitiligo combined with SLE, who quickly re-pigmented after treatment with tofacitinib and experienced no adverse reactions. It is reported as follows. A 56-year-old female with stably controlled SLE was diagnosed 10 years prior and currently taking 5 mg/d oral prednisone. She followed up at the rheumatology clinic every six months. One month prior, a white macular rash appeared on the patient's forehead with a rapidly expanding area. Dermatological examination revealed a white patch on the forehead measuring approximately 2.5cm×1.5 cm with clear borders (Figure 1). Reflectance confocal microscopy (RCM) revealed complete depigmentation of the basal layer of the epidermis (Figure 2). The final diagnosis was vitiligo. Relevant imaging and laboratory tests were performed, including frontal and lateral chest radiographs, electrocardiography, complete blood count, liver function tests, kidney function tests, plasma lipid levels, D-dimer, erythrocyte sedimentation rate, rheumatoid factor, antinuclear antibodies, anti-dsDNA antibodies, complements, thyroid antibody, immunoglobulins, antibodies to various infectious diseases such as syphilis, hepatitis B, hepatitis C, HIV, tumor markers such as CEA, CA199, AFP, and PPD test; no significant abnormalities were observed. Considering that the patient is currently using glucocorticoids to treat SLE, and she refused to add the dose of glucocorticoid to treat vitiligo. After obtaining the patient's written informed consent, the patient was given 10 mg/d oral tofacitinib, without the combination of phototherapy and topical medication. After 30 days, the white macular rash was completely re-pigmented (Figure 3), the pigment granules in the basal layer of the epidermis returned to normal on RCM (Figure 4), and no significant abnormalities were found on imaging and laboratory examination, including frontal and lateral chest radiographs, complete blood count, liver function tests, kidney function tests, plasma lipid levels, D-dimer, hepatitis B, and PPD test. No recurrence was observed at the 6-month follow-up, and the condition of SLE is stable. Figure 1 Before treatment, approximately 2.5cm × 1.5 cm white patches on the patient's forehead. Figure 2 Before treatment, reflectance confocal microscopy (RCM) revealed complete depigmentation -Abstract Truncated-
dermatology